Showing results (5081-5090 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|April 8, 2021
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K Choueiri, Yousef Zakharia, Sumanta Pal, et al.
The Oncologist|April 12, 2021
Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung CancerMonica Peravali, Jaeil Ahn, Kevin Chen, et al.
The Oncologist|August 1, 2020
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority TrialMaurice J D L van der Vorst, Elisa C Toffoli, Marlien Beusink, et al.
The Oncologist|July 14, 2020
Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian CancerTamar Safra, Barliz Waissengrin, Talya Levy, et al.
The Oncologist|August 14, 2020
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical TrialsCarmen Criscitiello, Antonio Marra, Stefania Morganti, et al.
The Oncologist|August 4, 2020
High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with CancerAnne-Laure Couderc, Eddy Puchades, Patrick Villani, et al.
The Oncologist|August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric CancersSurendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
The Oncologist|April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experienceRichard M Bambury, David J Benjamin, Joshua L Chaim, et al.
The Oncologist|April 22, 2021
Pancreas Cancer-Associated Pain ManagementAndrew L Coveler, Jonathan Mizrahi, Bory Eastman, et al.
The Oncologist|April 27, 2021
Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell SarcomaLucas R Massoth, Yin P Hung, Judith A Ferry, et al.
Pageof 571